- Medix Biochemica收购了美国Biostride业务，Biostride是药物滥用、激素类检测用原料的领先生产商，有着为全球体外诊断市场服务的悠久历史
Medix Biochemica has acquired the business of US-based Biostride Inc, a pioneering manufacturer of Drugs of Abuse and Hormone Testing bioreagents with a long history of serving the In-Vitro Diagnostic (IVD) industry worldwide

- 通过此次并购，Biostride将得以通过Medix的全球网络和北美、欧洲、中国的本地团队向全球客户提供其药物滥用、激素类等领域的出色产品
As a result of the acquisition, Biostride's leading portfolio of Drugs of Abuse antibodies and antigens will be available to the global IVD and drug testing customer base through Medix's comprehensive global sales network, with local presence in North America, Europe and China

- 此次并购还会将Biostride的产品纳入Medix Biochemica经ISO13485认证的生产标准中
The acquisition will also bring Biostride's products under Medix Biochemica's ISO13485 certified manufacturing standard

- 本次并购与Medix通过供应链整合、成为IVD行业首选的关键原料供应商的长期战略一致
The acquisition is in line with Medix’s strategy to consolidate the IVD supply chain and become the #1 supplier of critical raw materials to the IVD industry

- Biostride的共同创始人Laura Colin以及总裁Todd Corneillie将在随后的整合中继续担任Medix Biochemica的顾问
Biostride's co-founder Laura Colin and President Todd Corneillie will continue as advisors to Medix Biochemica following the transaction

通过收购Biostride业务，Medix Biochemica将其IVD产业关键原料产品线扩充到药物滥用相关抗体、抗原领域。并购后，Biostride业务将并入Medix Biochemica免疫诊断原料业务部。Biostride的共同创始人Laura Colin以及总裁Todd Corneillie将在随后的整合中继续担任Medix Biochemica的顾问。
Medix Biochemica has acquired the business of Biostride to expand its portfolio of key raw materials for the in vitro diagnostics (“IVD”) industry into Drugs of Abuse antibodies and antigens. As a result of the transaction, the operations of Biostride will be merged with Medix Biochemica's Immunodiagnostic Reagents Business Unit, and Biostride's co-founder Laura Colin and President Todd Corneillie will continue as advisors to Medix Biochemica.

Biostride由Laura Colin和Henry Tom创建于1990年，是全球IVD产业的抗体、抗原、及酶标记抗体、抗原的研发及生产商，以其药物滥用及激素检测相关原料而知名。Biostride总部位于美国加利福尼亚Redwood市。
Founded in 1990 by Laura Colin and Henry Tom, Biostride is a researcher, developer and primary manufacturer of antibodies, antigen and enzyme conjugates for the IVD manufacturing industry worldwide.  The company is particularly well known for its main product lines of Drugs of Abuse and Hormone testing components. Biostride is headquartered in Redwood City, California.

“我们很高兴收购了Biostride，其抗体、抗原产品作为关键原料被大量全球领先的试剂盒生产商用于药物滥用检测产品的生产。本次并购会将Biostride的产品纳入Medix Biochemica经ISO13485认证的生产标准中，这与Medix通过供应链整合、成为IVD行业首选的关键原料供应商的长期战略完全一致”，Medix Biochemica集团首席执行官Steve Ferguson如此说。
“We are excited about the acquisition of Biostride, whose antibody and antigen products have been integrated as critical components into the Drug of Abuse tests of various world-leading test manufacturers. The acquisition will bring Biostride's products under Medix Biochemica's ISO 13485 certified manufacturing standard and is perfectly in line with Medix Biochemica's strategy to consolidate the IVD supply chain and become the #1 supplier of critical raw materials for IVD test manufacturers”, says Steve Ferguson, CEO of Medix Biochemica.

“加入Medix Biochemica对于Biostride来说是顺理成章的一步，我们相信Medix Biochemicar的大规模生产能力、基于北美、欧洲和中国的全球销售网络将使Biostride获益良多”，Biostride总裁Todd Corneillie说。
“Joining forces with Medix Biochemica is the natural next step in Biostride's journey. We are confident that Biostride will benefit from Medix Biochemica's large-scale manufacturing expertise and comprehensive global sales network, with local presence in North America, Europe and China”, says Todd Corneillie, President of Biostride.

如需更多信息，请联系：

For more information:

Medix Biochemica中国商务团队
Commercial Team of Medix Biochemica China
Tel +86 21 6811 9180, 6811 9181, 6811 9105
Email: medixchina@medixbiochemica.com